peptide
ARA-290 (Cibinitide)
emergingResearch Use OnlyInjection
Derived from EPO but modified to activate tissue repair without increasing red blood cells. Protects nerves, fights inflammation. Studied for neuropathy and sarcoidosis.
Key facts
- Classification
- Peptide — EPO-derived repair peptide that reduces nerve pain without affecting blood cells.
- Primary benefits
- Injury Healing (7/10) · Inflammation (7/10) · Brain & Cognition (5/10)
- Administration
- Injection
- Doses studied
- 2-4 mg subq daily for 28 days. Can be repeated after a break.
- Evidence strength
- Emerging — 20 peer-reviewed studies
- Stacks well with
- BPC-157, SS-31
- Legal status
- Research Use Only · not prescribable in US
Quick stats
- Type
- Peptide
- Administration
- Injection
- Studies referenced
- 20
- Stacks with
- 2 peptides
- Regulatory
- Research Use Only
Goal coverage · ARA-290 (Cibinitide)
🩹 Injury Healing7/10
🧊 Inflammation7/10
🧠 Brain & Cognition5/10
😌 Mood & Anxiety4/10